Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug ...

Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product ...

Drugmaker Merck & Co on Tuesday announced job and cost cuts it said will save $3 billion a year as it posted lower ...

Verona Pharma plc (NASDAQ:VRNA) is one of the best multibagger stocks according to hedge funds. On July 9, 2025, Merck & Co.

The company narrowed its full-year sales guidance range, saying it now expects sales in the range of $64.3 billion to $65.3 ...

Merck said it is embarking on a multi-year cost-savings plan, which includes cuts to its workforce and real-estate footprint, ...

Plunging sales of Merck’s blockbuster HPV vaccine in China have caused a sharp fall in the US pharma group’s earnings. In ...

On a per-share basis, the Rahway, New Jersey-based company said it had profit of $1.76. Earnings, adjusted for one-time gains and costs, were $2.13 per share. The results topped Wall Street ...

Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Merck & Co., Inc. stands seventh on our list and recently ...

Merck & Co., Inc. (NYSE:MRK) will release earnings results for the second quarter before the opening bell on Tuesday, July 29. Analysts expect the health care company to report quarterly earnings at ...

The move bolsters Merck’s lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.